| Affiliation: | 1. Division of Hematology, Department of Internal Medicine, University of Utah, Salt Lake City, Utah;2. Comprehensive Cancer Center, Ohio State University, Columbus, Ohio;3. Division of Cancer Medicine, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas;4. Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, Ohio;5. Division of Hematopathology, Department of Pathology, Ohio State University, Columbus, Ohio;6. Division of Medicine, Department of Haematology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia;7. Division of Cytogenetics, Department of Pathology, Ohio State University, Columbus, Ohio;8. Division of Medicinal Chemistry, College of Pharmacy, Ohio State University, Columbus, Ohio |
| Abstract: | Little is known about outcomes of patients with chronic lymphocytic leukemia (CLL) with del(17p13.1) karyotype at diagnosis. We reviewed 114 de novo del(17p13.1) CLL patients seen at our institution. Using proportional hazards models to identify pretreatment clinical variables significantly associated with treatment‐free survival (TFS) and overall survival (OS), we developed a simplified risk score for de novo del(17p13.1) CLL patients to predict TFS and OS based on these variables. These scores, particularly the very highest, can be utilized to identify high‐risk patients for expedient enrollment on clinical trials. Our data support careful observation for low‐risk patients, potentially preventing unnecessary use of aggressive therapies. Am. J. Hematol. 90:967–969, 2015. © 2015 Wiley Periodicals, Inc. |
